| Year |
Citation |
Score |
| 2016 |
Fan Y, Wu G, Su F, Li K, Xu L, Han X, Yan Y. Lipase oriented-immobilized on dendrimer-coated magnetic multi-walled carbon nanotubes toward catalyzing biodiesel production from waste vegetable oil Fuel. 178: 172-178. DOI: 10.1016/j.fuel.2016.03.071 |
0.368 |
|
| 2012 |
Higgins B, Kolinsky KD, Schostack K, Bollag G, Lee RJ, Su F, Packman K. Efficacy of vemurafenib (V), a selective (V600E)BRAF inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 494. PMID 27983017 DOI: 10.1200/Jco.2012.30.4_Suppl.494 |
0.386 |
|
| 2012 |
Higgins B, Kolinsky KD, Yang H, Kim MJ, Li JK, Go Z, Packman K, Bollag G, Su F. Efficacy of vemurafenib, a selective BRAF(V600E) inhibitor, in combination with a MEK inhibitor in BRAF(V600E) colorectal cancer models. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 488. PMID 27982943 DOI: 10.1200/Jco.2012.30.4_Suppl.488 |
0.448 |
|
| 2012 |
Baudy AR, Dogan T, Flores-Mercado JE, Hoeflich KP, Su F, van Bruggen N, Williams SP. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. Ejnmmi Research. 2: 22. PMID 22651703 DOI: 10.1186/2191-219X-2-22 |
0.381 |
|
| 2012 |
Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. The New England Journal of Medicine. 366: 207-15. PMID 22256804 DOI: 10.1056/Nejmoa1105358 |
0.335 |
|
| 2012 |
Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, Kolinsky K, Packman K, Kim MJ, Trunzer K, Lee RJ, Schostack K, Carter J, Albert T, Germer S, et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Research. 72: 969-78. PMID 22205714 DOI: 10.1158/0008-5472.Can-11-1875 |
0.615 |
|
| 2012 |
Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcox ME, Kopetz S, Heimbrook D, Lestini B, Bollag G, Su F. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Research. 72: 779-89. PMID 22180495 DOI: 10.1158/0008-5472.Can-11-2941 |
0.636 |
|
| 2012 |
Baudy AR, Dogan T, Flores JE, Hoeflich KP, Su F, Bruggen Nv, Williams SP. Abstract 911: Vemurafenib FDG-PET preclinical imaging outcomes across BRAF V600E mutant and resistant tumors Cancer Research. 72: 911-911. DOI: 10.1158/1538-7445.Am2012-911 |
0.371 |
|
| 2012 |
Yang H, Higgins B, Kolinsky K, Li J, Margolis R, Go Z, Railkar A, Packman K, Bollag G, Su F. Abstract 2156: Preclinical combinations of vemurafenib, a selective BRAF inhibitor, with other targeted therapies in BRAFV600Ecolorectal cancer models Cancer Research. 72: 2156-2156. DOI: 10.1158/1538-7445.Am2012-2156 |
0.454 |
|
| 2011 |
Su F, Yang H, Higgins B, Kolinsky KD, Packman K, Kim M, Lestini BJ, Bollag G, Heimbrook DC. Molecular mechanisms underlying disease relapse on treatment with selective BRAF inhibitor vemurafenib (PLX4032). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8517. PMID 28021139 DOI: 10.1200/Jco.2011.29.15_Suppl.8517 |
0.359 |
|
| 2011 |
Puzanov I, Flaherty KT, Sosman JA, Grippo JF, Su F, Nolop K, Lee RJ, Bollag G. Vemurafenib: B-raf kinase inhibitor, oncolytic Drugs of the Future. 36: 191-199. DOI: 10.1358/Dof.2011.036.03.1590788 |
0.411 |
|
| 2011 |
Higgins B, Kolinksy K, Go Z, Char H, Lee R, Schostack K, Bollag G, Heimbrook D, Su F, Packman KE. Abstract 2562: Efficacy of RG7204 (PLX4032), a selective BRAFV600Einhibitor, in combination with pegylated interferon alpha-2a (Pegasys), paclitaxel, carboplatin, and anti-VEGF MAb B20-4.1 in the LOX-IMVI human melanoma xenograft model Cancer Research. 71: 2562-2562. DOI: 10.1158/1538-7445.Am2011-2562 |
0.339 |
|
| 2010 |
Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, ... ... Su F, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 467: 596-9. PMID 20823850 DOI: 10.1038/Nature09454 |
0.424 |
|
| 2010 |
Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, Kolis S, Zhao S, Lee R, Grippo JF, Schostack K, Simcox ME, Heimbrook D, Bollag G, Su F. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Research. 70: 5518-27. PMID 20551065 DOI: 10.1158/0008-5472.Can-10-0646 |
0.373 |
|
| 2003 |
Soon LL, Yie TA, Shvarts A, Levine AJ, Su F, Tchou-Wong KM. Overexpression of WISP-1 down-regulated motility and invasion of lung cancer cells through inhibition of Rac activation. The Journal of Biological Chemistry. 278: 11465-70. PMID 12529380 DOI: 10.1074/jbc.M210945200 |
0.406 |
|
| 2002 |
Su F, Overholtzer M, Besser D, Levine AJ. WISP-1 attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase. Genes & Development. 16: 46-57. PMID 11782444 DOI: 10.1101/Gad.942902 |
0.584 |
|
| Show low-probability matches. |